DK2305245T3 - Behandling af sygdomme forbundet med anvendelsen af antibiotika - Google Patents

Behandling af sygdomme forbundet med anvendelsen af antibiotika Download PDF

Info

Publication number
DK2305245T3
DK2305245T3 DK10075450.6T DK10075450T DK2305245T3 DK 2305245 T3 DK2305245 T3 DK 2305245T3 DK 10075450 T DK10075450 T DK 10075450T DK 2305245 T3 DK2305245 T3 DK 2305245T3
Authority
DK
Denmark
Prior art keywords
compound
antibiotic
paragraph
difficile
administered
Prior art date
Application number
DK10075450.6T
Other languages
English (en)
Inventor
Youe-Kong Shue
Farah Kondori Babakhani
Franklin W Okumu
Pamela Suzanne Sears
Starr Louise Miller-Shangle
Robert Brian Walsh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK2305245T3 publication Critical patent/DK2305245T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Claims (8)

  1. BEHANDLING AF SYGDOMME FORBUNDET MED ANVENDELSEN AF ANTIBIOTIKA
    1. Tablet, der omfatter en forbindelse med formlen (II):
    til anvendelse i forebyggelse af tilbagevenden af antibiotika-associeret diarré hos en patient.
  2. 2. Tablet til anvendelse ifølge krav 1, hvor patienten er et menneske.
  3. 3. Tablet til anvendelse ifølge krav 1, hvor patienten er et pattedyr.
  4. 4. Tablet til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor forbindelsen er til administration i en mængde på ca. 10 mg til ca. 1 g.
  5. 5. Tablet til anvendelse ifølge krav 4, hvor tabletten omfatter forbindelsen i en mængde på ca. 50 mg til ca. 400 mg til administration én gang eller to gange dagligt.
  6. 6. Tablet til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor tabletten er til administration fra én til fire gange dagligt.
  7. 7. Tablet til anvendelse ifølge et hvilket som helst af kravene 1 til 6 til administration til patienten oralt.
  8. 8. Tablet til anvendelse ifølge et hvilket som helst af kravene 1 til 4 til administration fra én til fire gange dagligt i tre til femten dage.
DK10075450.6T 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelsen af antibiotika DK2305245T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57069704P 2004-05-14 2004-05-14
EP05748007A EP1765312B1 (en) 2004-05-14 2005-05-13 Treatment of diseases associated with the use of antibiotics

Publications (1)

Publication Number Publication Date
DK2305245T3 true DK2305245T3 (da) 2019-03-25

Family

ID=35428857

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10075449.8T DK2305244T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelse af antibiotika
DK10075450.6T DK2305245T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelsen af antibiotika
DK09156339.5T DK2070530T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelse af antibiotika

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10075449.8T DK2305244T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelse af antibiotika

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09156339.5T DK2070530T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelse af antibiotika

Country Status (17)

Country Link
US (2) US20070173462A1 (da)
EP (4) EP2305245B1 (da)
JP (2) JP5734545B2 (da)
AT (1) ATE516024T1 (da)
BR (1) BRPI0511119A (da)
CA (2) CA2776682A1 (da)
CY (2) CY1117501T1 (da)
DK (3) DK2305244T3 (da)
ES (4) ES2608046T3 (da)
HU (3) HUE027757T2 (da)
LT (1) LT2305245T (da)
MX (2) MX344601B (da)
PL (3) PL2070530T3 (da)
PT (2) PT2305244T (da)
SI (2) SI2305245T1 (da)
TR (1) TR201902533T4 (da)
WO (1) WO2005112990A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
JP5166040B2 (ja) * 2005-01-31 2013-03-21 オプティマー ファーマシューティカルズ、インコーポレイテッド １８員大環状化合物及びその類似化合物
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
JP2009512691A (ja) * 2005-10-21 2009-03-26 オプティマー ファーマシューティカルズ，インコーポレーテッド クロストリジウムディフィシレ関連の下痢の治療方法
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
WO2009117310A2 (en) * 2008-03-17 2009-09-24 Cedars-Sinai Medical Center Methods for treatment and prevention of mrsa/mssa
EP2485742A4 (en) * 2009-10-06 2013-03-20 Scott Dorfner ANTIBIOTIC FORMULATIONS WITH REDUCED SIDE EFFECTS ON STOMACH AND DARM
CA2780912A1 (en) * 2009-11-17 2011-05-26 Piramal Life Sciences Limited Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders
WO2011082218A1 (en) * 2009-12-31 2011-07-07 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
CA2799386A1 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Treatment of clostridium difficile infection in patients undergoing antibiotic therapy
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
DK3139932T3 (da) * 2014-05-09 2018-11-12 Astellas Pharma Europe Ltd Behandlingsregimen for tiacumicin-forbindelse

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279995A (en) 1963-05-31 1966-10-18 Allen F Reid Shaped pellets
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
IN186245B (da) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
WO2003085089A2 (en) * 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
CN100519757C (zh) * 2002-07-29 2009-07-29 浩鼎生技公司 台勾霉素的制备
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
MXPA06013245A (es) 2007-05-09
EP2305245B1 (en) 2019-01-02
PT2305245T (pt) 2019-03-19
EP2305245A1 (en) 2011-04-06
CY1121284T1 (el) 2020-05-29
EP1765312A2 (en) 2007-03-28
LT2305245T (lt) 2019-03-12
EP2070530A1 (en) 2009-06-17
BRPI0511119A (pt) 2007-11-27
EP2305244B1 (en) 2016-10-12
CY1117501T1 (el) 2017-04-26
DK2070530T3 (da) 2016-05-17
ES2395404T3 (es) 2013-02-12
HUE031581T2 (en) 2017-07-28
PL2305244T3 (pl) 2017-04-28
US20130274175A1 (en) 2013-10-17
MX344601B (es) 2016-12-20
JP6101010B2 (ja) 2017-03-22
ES2608046T3 (es) 2017-04-05
WO2005112990A2 (en) 2005-12-01
WO2005112990A3 (en) 2006-01-05
US20070173462A1 (en) 2007-07-26
DK2305244T3 (da) 2017-01-30
JP5734545B2 (ja) 2015-06-17
CA2776682A1 (en) 2005-12-01
PT2305244T (pt) 2016-12-29
EP1765312A4 (en) 2007-08-22
PL2305245T3 (pl) 2019-05-31
JP2012197309A (ja) 2012-10-18
CA2566687C (en) 2012-07-24
ATE516024T1 (de) 2011-07-15
HUE027757T2 (en) 2016-11-28
ES2713954T3 (es) 2019-05-24
CA2566687A1 (en) 2005-12-01
SI2305245T1 (sl) 2019-04-30
JP2007537290A (ja) 2007-12-20
TR201902533T4 (tr) 2019-03-21
EP1765312B1 (en) 2011-07-13
EP2070530B1 (en) 2016-02-17
ES2565609T3 (es) 2016-04-05
EP2305244A1 (en) 2011-04-06
HUE043945T2 (hu) 2019-09-30
SI2070530T1 (sl) 2016-05-31
PL2070530T3 (pl) 2016-06-30

Similar Documents

Publication Publication Date Title
DK2305245T3 (da) Behandling af sygdomme forbundet med anvendelsen af antibiotika
CA2596387C (en) 18-membered macrocycles and analogs thereof
EP2222309B1 (en) Antibiotic macrocycle compounds and methods of manufacture and use thereof
DK2337575T3 (da) Fremgangsmåde til behandling med enkeltdoser af oritavancin
US20040147441A1 (en) Methods and reagents for preventing bacteremias
JP2009512691A (ja) クロストリジウムディフィシレ関連の下痢の治療方法
AU2013245517B2 (en) 18-membered macrocycles and analogs thereof
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
JP2012229264A (ja) １８員大環状化合物及びその類似化合物